AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

Betsy Goodfellow | July 8, 2024 | News story | Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer 

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 mutations.

This approval follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and is based on results from the phase 3 FLAURA2 trial which were published in The New England Journal of Medicine.

In this trial, Tagrisso, combined with chemotherapy, reduced the risk of disease progression or death by 38% by investigator assessment compared to the drug as a monotherapy, which is the current standard of care.

Advertisement

Median progression-free survival (PFS) was 25.5 months for patients treated with the drug combination, compared to 16.7 months for the group on the monotherapy.

Dave Fredrickson, executive vice president of the oncology business unit at AstraZeneca, commented: “This approval reinforces Tagrisso as the backbone therapy in EGFR-mutated lung cancer either as monotherapy or in combination with chemotherapy. This is especially important for those with more aggressive disease, including patients whose cancer has spread to the brain and those with L858R mutations.”

Betsy Goodfellow

Related Content

HUTCHMED completes enrolment in phase 3 trial for lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

The Gateway to Local Adoption Series

Latest content